The clinical cure diagnosis is based on resolution or improvement of signs and symptoms associated with AECB, without the need for additional therapy. This analysis was conducted among clinically evaluable patients, which included those who were diagnosed with AECB at the start of the study, took the medication for at least three days, had not taken other antimicrobial agents prior to starting the study and attended the final study visit. In addition to physician assessment of efficacy of the two study medications, patients were asked to assess their condition by answering a questionnaire. Patients were monitored for improvement or resolution of pretreatment signs and symptoms throughout the study. However, a significant difference was observed at study days 10-12 in the volume of sputum produced.
Chronic bronchitis is the seventh most prevalent of all chronic conditions.
It is characterized by the presence of mucus-producing cough and obstructed airflow for at least three consecutive months a year for two successive years. In patients with a known hypersensitivity to clarithromycin or any macrolide antibiotic, Biaxin XL tablets are contraindicated. Biaxin XL tablets should not be used in pregnant women except in circumstances for which no alternative therapy is appropriate. Biaxin XL tablets may elevate digoxin serum concentration. Serum digoxin levels should be carefully monitored while digoxin and clarithromycin are taken concomitantly.